674 related articles for article (PubMed ID: 12885750)
1. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
Kaufmann H; Saadia D; Voustianiouk A; Goldstein DS; Holmes C; Yahr MD; Nardin R; Freeman R
Circulation; 2003 Aug; 108(6):724-8. PubMed ID: 12885750
[TBL] [Abstract][Full Text] [Related]
2. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.
Goldstein DS
Cardiovasc Drug Rev; 2006; 24(3-4):189-203. PubMed ID: 17214596
[TBL] [Abstract][Full Text] [Related]
3. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
Mathias CJ; Senard JM; Braune S; Watson L; Aragishi A; Keeling JE; Taylor MD
Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
[TBL] [Abstract][Full Text] [Related]
4. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Lamotte G; Holmes C; Sullivan P; Goldstein DS
Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.
Goldstein DS; Holmes C; Kaufmann H; Freeman R
Clin Auton Res; 2004 Dec; 14(6):363-8. PubMed ID: 15666063
[TBL] [Abstract][Full Text] [Related]
6. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Kaufmann H
Clin Auton Res; 2008 Mar; 18 Suppl 1():19-24. PubMed ID: 18368303
[TBL] [Abstract][Full Text] [Related]
7. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
Freeman R; Landsberg L; Young J
Neurology; 1999 Dec; 53(9):2151-7. PubMed ID: 10599797
[TBL] [Abstract][Full Text] [Related]
8. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.
Kaufmann H
J Neural Transm Suppl; 2006; (70):477-84. PubMed ID: 17017570
[TBL] [Abstract][Full Text] [Related]
9. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Goldstein DS; Holmes C; Sewell L; Pechnik S; Kopin IJ
J Clin Pharmacol; 2011 Jan; 51(1):66-74. PubMed ID: 20220040
[TBL] [Abstract][Full Text] [Related]
10. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Palma JA; Norcliffe-Kaufmann L; Martinez J; Kaufmann H
Neurology; 2018 Oct; 91(16):e1539-e1544. PubMed ID: 30232253
[TBL] [Abstract][Full Text] [Related]
11. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Iida N; Koshikawa S; Akizawa T; Tsubakihara Y; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M
Am J Nephrol; 2002; 22(4):338-46. PubMed ID: 12169865
[TBL] [Abstract][Full Text] [Related]
12. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H; Freeman R; Biaggioni I; Low P; Pedder S; Hewitt LA; Mauney J; Feirtag M; Mathias CJ;
Neurology; 2014 Jul; 83(4):328-35. PubMed ID: 24944260
[TBL] [Abstract][Full Text] [Related]
13. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
Hauser RA; Hewitt LA; Isaacson S
J Parkinsons Dis; 2014; 4(1):57-65. PubMed ID: 24326693
[TBL] [Abstract][Full Text] [Related]
14. Droxidopa in neurogenic orthostatic hypotension.
Kaufmann H; Norcliffe-Kaufmann L; Palma JA
Expert Rev Cardiovasc Ther; 2015; 13(8):875-91. PubMed ID: 26092297
[TBL] [Abstract][Full Text] [Related]
15. Beneficial attenuating effect of L-threo-3,4-dihydroxyphenylserine on postural hypotension in anesthetized rats.
Satoh S; Oyabe A; Tanno M; Suzuki-Kusaba M
Arzneimittelforschung; 1989 Sep; 39(9):1123-9. PubMed ID: 2511849
[TBL] [Abstract][Full Text] [Related]
16. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
Isaacson SH; Skettini J
Vasc Health Risk Manag; 2014; 10():169-76. PubMed ID: 24729712
[TBL] [Abstract][Full Text] [Related]
17. [Effects of L-threo-Dops on orthostatic hypotension in Parkinson's disease].
Yanagisawa N; Ikeda S; Hashimoto T; Hanyu N; Nakagawa S; Fujimori N; Ushiyama M
No To Shinkei; 1998 Feb; 50(2):157-63. PubMed ID: 9513205
[TBL] [Abstract][Full Text] [Related]
18. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Biaggioni I; Freeman R; Mathias CJ; Low P; Hewitt LA; Kaufmann H;
Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
[TBL] [Abstract][Full Text] [Related]
19. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
Hauser RA; Isaacson S; Lisk JP; Hewitt LA; Rowse G
Mov Disord; 2015 Apr; 30(5):646-54. PubMed ID: 25487613
[TBL] [Abstract][Full Text] [Related]
20. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]